- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04630431
Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations for the Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer Patients
Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations: Development and Validation of a Personalized Clinical Trial Educational Platform to Boost Participation Among Underserved Cancer Patients
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To understand and document patient preferences, understanding, and attitudes regarding clinical trials.
II. To compare patient attitudes regarding clinical trials among cancer patients belonging to different racial/ethnic groups.
III. To establish the magnitude of existing knowledge gap relating to clinical trials among underserved cancer patients and the extent of improvement with a personalized educational approach.
IV. To determine how a personalized educational approach impacts enrollment in clinical trials of underserved cancer patients.
OUTLINE:
PART I: Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials. Patients also have their medical records reviewed.
PART II: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo clinical trial education via a video and educational booklet and then standard of care follow-up on study.
ARM B: Patients undergo clinical trial education via a video and educational booklet and then undergo patient navigation with active clinical trial matching and receive clinical trial information through the electronic medical record portal on study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic in Arizona
-
Principal Investigator:
- Cassandra N. Moore, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Florida
-
Jacksonville, Florida, United States, 32224-9980
- Recruiting
- Mayo Clinic in Florida
-
Principal Investigator:
- Sikander Ailawadhi, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Principal Investigator:
- Rahma M. Warsame, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- PART I: Subjects must be adults with age >= 18 years at the time of study entry
- PART I: Subjects with any cancer diagnosis may be included
- PART I: Subjects must be identified as new patients to hematology oncology at the treating site
- PART I: Subjects must be willing to provide informed consent for the study
- PART II: Subjects must be adults with age >= 18 years at the time of study entry
- PART II: Subjects with any cancer diagnosis may be included
- PART II: Subjects must be identified as new patients to hematology oncology at the treating site
- PART II: Subjects must be willing to provide informed consent for the study
Exclusion Criteria:
- PART I: Patients reported to have an estimated life-expectancy of < 6 months, as assessed by their clinician
- PART I: Patients not willing to complete the Clinical Trials Study survey
- PART II: Patients reported to have an estimated life-expectancy of < 6 months, as assessed by their clinician
- PART II: Patients not willing to complete the education intervention or continued follow up for at least 2 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part I (questionnaire, medical record review)
Patients complete a questionnaire about their preferences, understanding, and attitudes regarding clinical trials.
Patients also have their medical records reviewed.
|
Complete questionnaire
Review of medical record
|
Active Comparator: Part II: Arm A (clinical trial education, standard of care)
Patients undergo clinical trial education via a video and educational booklet and then standard of care follow-up on study.
|
Complete questionnaire
Review of medical record
Undergo standard of care follow-up
Other Names:
Undergo clinical trial education via a video and educational booklet
Other Names:
|
Experimental: Part II: Arm B (clinical trial education, navigation)
Patients undergo clinical trial education via a video and educational booklet and then undergo patient navigation with active clinical trial matching and receive clinical trial information through the electronic medical record portal on study.
|
Complete questionnaire
Review of medical record
Undergo standard of care follow-up
Other Names:
Undergo clinical trial education via a video and educational booklet
Other Names:
Undergo clinical trial navigation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Documentation of patient preferences, understanding, and attitudes regarding clinical trials (part I)
Time Frame: Baseline
|
Overall percentages of the individual categories for each item of the survey will be summarized across all individuals.
Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data.
Any categorical items will be potentially compared between groups using Chi-square tests.
Continuous measures maybe compared using analysis of variance.
Most of this analysis will be exploratory though and viewed as hypothesis generating.
|
Baseline
|
Comparison of patient attitudes regarding clinical trials among cancer patients belonging to different racial/ethnic groups (part I)
Time Frame: Baseline
|
Overall percentages of the individual categories for each item of the survey will be summarized across all individuals.
Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data.
Any categorical items will be potentially compared between groups using Chi-square tests.
Continuous measures maybe compared using analysis of variance.
Most of this analysis will be exploratory though and viewed as hypothesis generating.
|
Baseline
|
Knowledge score (part II)
Time Frame: Baseline
|
Linear regression to compare knowledge score at baseline in underserved groups with the rest of the cancer patients in the study with adjustment for relevant covariates.
We will obtain an estimate of the difference in mean scores along with a 95% confidence interval (CI).
|
Baseline
|
Change in knowledge score (part II)
Time Frame: Baseline up to 6 and 12 months
|
Linear regression to compare change in knowledge score in patients enrolled in the educational intervention versus in the comparator arm.
We will adjust for baseline score and obtain an estimated of the difference in mean score change along with a 95% CI.
|
Baseline up to 6 and 12 months
|
Patient enrollment in a clinical trial
Time Frame: Up to 24 months
|
The binary outcome of whether or not each patient is enrolled in a trial or not, focusing on the underserved patients.
A predetermined randomization algorithm/schedule will be utilized.
Logistic regression will be used to compare the proportion of patients enrolled in a trial in each of the two study arms.
Adjustments will be made for baseline covariates known to be associated with trial participation.
A likelihood ratio test will be conducted of the null hypothesis of no difference in proportions in the two groups.
The associated odds ratio will be estimated along with a 95% CI.
Comparisons will also be made with the non-underserved patients in which the proportion enrolling in trials is expected to be much higher, with or without the intervention.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association of baseline patient characteristics (socioeconomic status, level of education, social support, among others) with the patient's preferences and understanding regarding clinical trials (part I)
Time Frame: Baseline
|
Will be obtained from the Epic electronic medical record and from the baseline survey.
Overall percentages of the individual categories for each item of the survey will be summarized across all individuals.
Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data.
Any categorical items will be potentially compared between groups using Chi-square tests.
Continuous measures maybe compared using analysis of variance.
Most of this analysis will be exploratory though and viewed as hypothesis generating.
|
Baseline
|
Association of disease state (newly diagnosed versus previously treated) with patients understanding and behavior towards clinical trial participation (part I)
Time Frame: Baseline
|
Overall percentages of the individual categories for each item of the survey will be summarized across all individuals.
Any continuous items collected will be summarized using Means and/or medians depending on the distribution of the data.
Any categorical items will be potentially compared between groups using Chi-square tests.
Continuous measures maybe compared using analysis of variance.
Most of this analysis will be exploratory though and viewed as hypothesis generating.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sikander Ailawadhi, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC220901
- 19-004014 (Other Identifier: Mayo Clinic)
- NCI-2020-08521 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation